Gastrointestinal Stromal Tumor Of Stomach Research Articles

Factors associated with gastrointestinal stromal tumor rupture and pathological risk: A single-center retrospective study.

Gastrointestinal stromal tumor (GIST) is a rare gastrointestinal mesenchymal tumor with potential malignancy. Once the tumor ruptures, regardless of tumor size and mitotic number, it can be identified into a high-risk group. It is of great significance for the diagnosis, treatment, and prognosis of GIST if non-invasive examination can be performed before surgery to accurately assess the risk of tumor. To identify the factors associated with GIST rupture and pathological risk. A cohort of 50 patients with GISTs, as confirmed by postoperative pathology, was selected from our hospital. Clinicopathological and computed tomography data of the patients were collected. Logistic regression analysis was used to evaluate factors associated with GIST rupture and pathological risk grade. Pathological risk grade, tumor diameter, tumor morphology, internal necrosis, gas-liquid interface, and Ki-67 index exhibited significant associations with GIST rupture (P < 0.05). Gender, tumor diameter, tumor rupture, and Ki-67 index were found to be correlated with pathological risk grade of GIST (P < 0.05). Multifactorial logistic regression analysis revealed that male gender and tumor diameter ≥ 10 cm were independent predictors of a high pathological risk grade of GIST [odds ratio (OR) = 11.12, 95% confidence interval (95%CI): 1.81-68.52, P = 0.01; OR = 22.96, 95%CI: 2.19-240.93, P = 0.01]. Tumor diameter ≥ 10 cm, irregular shape, internal necrosis, gas-liquid interface, and Ki-67 index ≥ 10 were identified as independent predictors of a high risk of GIST rupture (OR = 9.67, 95%CI: 2.15-43.56, P = 0.01; OR = 35.44, 95%CI: 4.01-313.38, P < 0.01; OR = 18.75, 95%CI: 3.40-103.34, P < 0.01; OR = 27.00, 95%CI: 3.10-235.02, P < 0.01; OR = 4.43, 95%CI: 1.10-17.92, P = 0.04). Tumor diameter, tumor morphology, internal necrosis, gas-liquid, and Ki-67 index are associated with GIST rupture, while gender and tumor diameter are linked to the pathological risk of GIST. These findings contribute to our understanding of GIST and may inform non-invasive examination strategies and risk assessment for this condition.

Is Bleeding Gastrointestinal Stromal Tumor Associated With Higher MortalityandMorbidity?

Introduction Gastrointestinal stromal tumor (GIST) is the most common primary mesenchymal tumor of the gastrointestinal tract. The clinical presentation of GIST varies widely and ranges from being asymptomatic to being a life-threatening emergency in the form of gastrointestinal bleeding or bowel obstruction. Multiple prognostic factors have been identified for GIST, including, most importantly, larger tumor size (>5 cm), higher mitotic activity (>5 per 50 high-power fields), rupture of the mass, site of the mass, and personal history of GIST. Objective In this paper, we aim to study bleeding in gastrointestinal tumors as a predictor for morbidity and mortality and investigate possible factors influencing bleeding in GIST. Method A retrospective study design was used. Electronic medical records of 39 patients diagnosed with GIST in Prince Sultan Military Medical City in Riyadh between January 2015 and December 2020 were retrieved. Normal variables were presented as mean and standard deviation, while non-normal variables were presented as median and interquartile range. Student t-test or Mann-Whitney test was used to compare quantitative data when appropriate. The distribution of recurrence and survival was plotted with the Kaplan-Meier curveand compared between the two groups (bleeding and non-bleeding groups) with the log-rank test. Factors affecting recurrence and mortality were assessed using univariable Cox regression. Result A total of 39 cases of GIST tumors were included in this study. Patients were categorized according to the presentation into two groups: patients with no bleeding (n= 28) and those presented with bleeding (n= 11). The gender distribution was equal. The mean age was 58.14± 12.46 in patients with non-bleeding GIST and 58.18± 16.01 in patients with bleeding GIST. The most common location of GIST was the stomach (22 cases, 56%). Neither group had any significant differences regarding age (P-value = 0.993), gender (P-value = 0.648), tumor location (P-value = 0.057), size (P-value = 0.250), cluster of differentiation (CD) markers, histological types (P-value = 0.692), and shape (P-value = 0.079). There was no significant difference in recurrence between both groups (log-rank P = 0.972). There was no significant difference in survival between both groups (Log-rank P = 0.506). Conclusion We concluded that bleeding GIST was not a significant predictor for recurrence rate or higher mortality. This can help in the debate of whether bleeding GIST should be added as an independent factor in risk stratification. Despite that, further studies are needed to identify more variables that can add more accuracy to the pre-existing risk stratification systems.

Gastrointestinal bleeding caused by a hidden gastrointestinal stromal tumor of the stomach

Gastrointestinal stromal tumors (GISTs) are the most common type of mesenchymal tumor of the gastrointestinal tract. This report presents a case of a large exophytic stomach GIST that was not visible at esophagogastroduodenoscopy (EGD). A 70-year-old female presented to the emergency room with presyncopal symptoms and a history of several episodes of melena. Blood tests revealed severe anemia. She underwent an EGD, which yielded negative results. Subsequently, she was hospitalized and scheduled for ileo-colonscopy and videocapsule enteroscopy (VCE). Abdominal ultrasound showed the presence of a mass in the epigastric region near the liver. Computed tomography (CT) scans confirmed the presence of a mass in the gastric wall that, at endoscopic ultrasound (EUS) exam and biopsy, was diagnosed as a tumor that originated from the muscular layer of the stomach. Surgery was performed to excise the tumor, and the diagnosis of GIST was confirmed by histomorphological and immunohistochemical findings. According to the postoperative assessment, the tumor was classified as high risk, for which the recommended treatment is imatinib.

An observational study of gastrointestinal stromal tumors by histopathology and immunohistochemistry

Introduction: Gastrointestinal stromal tumors (GIST) are the most common mesenchymal neoplasms of the gastrointestinal tract and their diagnosis is mainly based on histopathology and immunohistochemical study with CD117 marker. However, there are many GIST tumors that are CD117 negative and for such cases come the role of other IHC markers. The study aimed to observe the various histological features and demographic profiles of GISTs and the role of various immunohistochemical markers in the confirmation of diagnosis. Methodology: A hospital-based observational study was conducted on 40 tumor resection materials diagnosed as GIST from April 2017 to February 2023 at tertiary care center K.E.M. Hospital, Pune. All the cases underwent histopathological examination with standard procedure of tissue processing, staining and IHC with CD117. Those cases who were morphologically designated as GIST on HPE were evaluated with a panel of IHC markers like C-KIT, CD34, SMA, desmin, S-100 and vimentin. Results: 35 out of 40 cases (87.5%) were found to be positive for CD117 while IHC markers like CD34, SMA, desmin, S-100 and vimentin were found to be positive in 60%, 20%, 5%, 2.5% and 80% cases respectively. Also, we found significant relationship between histopathological groups different progressive disease risk groups with necrosis, cytologic atypia, cellularity and mucosal invasion (p-value&lt;0.05) Conclusion: In a nutshell, a GIST diagnosis should not be precluded on the basis of morphology only. Use of immunohistochemistry is vital to rule out other mesenchymal tumors and confirmation of GIST. Keywords: GIST; gastrointestinal stromal tumors; IHC; CD 117; histopathology; c-KIT

Liver resection for metastatic GIST tumor improves survival in the era of tyrosine kinase inhibitors: a systematic review and meta-analysis.

Survival for gastrointestinal stromal tumor (GIST) has been increasing over the years after the introduction of tyrosine kinase inhibitors. However, the role of metastasectomy for GIST is still controversial. Patients are currently treated with imatinib or sunitinib in case of imatinib failures as optimal medical therapy for metastatic GIST. The Pubmed, EMBASE, and Cochrane Library were systematically searched. Overall survival following liver resection ± tyrosine kinase inhibitor treatment for metastatic GIST was compared to treatment with tyrosine kinase inhibitors alone. Eleven studies including both randomized control trials and retrospective cohort studies were included in the final analysis with a total of 988 patients. Seven studies encompassed data on 556 patients with isolated liver metastases (219 surgery ± drug groups and 337 drug-only groups) were included. Overall survival was significantly improved in patients undergoing liver resection ± drug therapy in comparison to drug therapy alone. [HR (95%CI) = 2.10 (1.58, 2.79); p<0.00001]. Subgroup analysis showed that patients also had improved progression free survival based on 4 studies. [HR (95%CI) = 1.92 (1.43, 2.56); p<0.00001]. In case of concurrent liver and peritoneal metastases, patients showed improved overall survival with aggressive surgical approaches based on 10 studies. [HR (95%CI) = 1.90 (1.56, 2.31); p<0.00001]. This meta-analysis found that liver resection for patients with metastatic GIST regardless of peritoneal metastases improved progression free and overall survival in conjunction with tyrosine kinase inhibitors as compared with medical therapy alone. Furthermore, liver resections did not have any immediate detrimental impact on survival in the group of patients selected.

DOG1 expression in neuroendocrine neoplasms: Potential applications and diagnostic pitfalls

Neuroendocrine neoplasms represent a heterogeneous group of rare tumors, more frequently arising from gastroenteropancreatic tract and lungs. At the time of diagnosis, 20% of cases are metastatic, and 10% of cases are considered as cancer of unknown primary origin. Several immunohistochemical markers are routinely used to confirm the neuroendocrine differentiation, first among all Synaptophysin and Chromogranin-A; on the other hand, different immunohistochemical markers are used to establish primary anatomical site, as TTF1, CDX2, Islet-1 and Calcitonin, but no marker is available in order to distinguish among different sites of the digestive tract.DOG1 (discovered on GIST-1) is a gene normally expressed in interstitial cells of Cajal and, in routine practice, DOG1 immunostaining is used in diagnosis of GIST (gastrointestinal stromal tumor). DOG1 expression has been described in several neoplasms other than GIST, both in mesenchymal and epithelial neoplasms. In the present study, DOG1 immunostaining has been performed in a large cohort of neuroendocrine neoplasms, including neuroendocrine tumors and neuroendocrine carcinomas, in order to evaluate frequency, intensity and pattern of expression in different anatomical site and in different tumor grade. DOG1 expression was detected in a large percentage of neuroendocrine tumors, with statistically significant association between DOG1 expression and gastrointestinal tract neuroendocrine tumors. As a consequence, DOG1 could be included in marker panel for the identification of primary site in neuroendocrine metastases of unknown primary origin; moreover, these results recommend careful evaluation of DOG1 expression in gastrointestinal neoplasms, in particular in differential diagnosis between epithelioid GIST and neuroendocrine tumors.

The association of genitourinary cancer among Saudi patients with gastrointestinal stromal tumors and a systematic literature review

The gastrointestinal tract's most commonly occurring primary mesenchymal tumor is the gastrointestinal stromal tumor (GIST). However, few cases worldwide were reported associated with renal cell carcinoma (RCC). Therefore, we aimed to identify the association of genitourinary tumors in patients with GIST in our tertiary care hospital in Saudi Arabia and compare it to the literature. We identified all patients in the pathology department database with the diagnosis of GIST. We excluded duplicate and recurrent cases. We examined patients’ files for the presence of RCC, adrenal tumors, or other genitourinary cancer. A systematic review of the association was conducted. From 2003 to 2020, 170 patients had a histopathologic diagnosis of primary GIST, 100 men and 70 women, median age of 57 (range 9–91) years at the time of diagnosis. The site of primary GIST was gastric 103, small bowel 43, mesenteric 5, omentum/peritoneum 7, abdomen 4, isolated adrenal 1, and other 7. Six patients had associated primary genitourinary cancer. Three patients had RCC (two clear cell RCC and one radiologic diagnosis only), and three had adrenal tumors (one adrenal carcinoma, one an isolated adrenal GIST, and one pheochromocytoma). In addition, two patients had a tumor invading the urinary bladder. Although the cohort included 63 men aged 60 or above (median 71 ± 8.7 years, range 60–94), none demonstrated clinical prostatic carcinoma. Data was compared to 69 systematic review articles. We report the rare association between GIST tumors and primary genitourinary cancer, mainly RCC and adrenal tumors. Also, we identified a secondary invasion of the urinary bladder. Unlike the reported series, none of the older male patients had clinical prostate cancer.

Tumor-associated macrophages mediate gastrointestinal stromal tumor cell metastasis through CXCL2/CXCR2.

Tumor-associated macrophages (TAMs) are linked with the progression and poor prognosis of multifarious solid tumors, but the regulatory mechanisms involved in gastrointestinal stromal tumors (GIST) remain indistinct. This study intended to delve into the job of TAM-derived chemokines in promoting metastasis in GIST microenvironment. Expression levels of M2-TAM markers and CXCL2 in primary and metastatic tissues of GIST were analyzed by bioinformatics methods, and we analyzed the correlation between CXCL2 and M2-TAM markers. Immunofluorescence was applied to assay CXCL2 and M2-TAM marker protein (CD68 and CD206) expression in tumor tissues. Serum CXCL2 concentration in metastatic and non-metastatic patients was assayed by ELISA. The differentiation of THP-1 cells was tested by flow cytometry. Cell function test was utilized to analyze the viability, invasion and migration of GIST cells. Western blot was used to examine the expression of epithelial-mesenchymal transition (EMT)-related proteins. The mouse liver metastasis model was established, and the effects of CXCL2 and EMT-related genes on metastasis were confirmed by hematoxylin-eosin staining and immunohistochemistry experiments. Bioinformatics analysis ascertained that M2-TAM marker proteins and chemokine CXCL2 were highly expressed in GIST metastatic tissues, and CXCL2 and TAM were co-located in tumor tissues. Results of in vitro cell function experiments displayed that CXCL2 secreted by M2-TAM promoted the invasion, migration and EMT of GIST tumor cells, and the anti-CXCL2 antibody could block the metastasis promoting effect of CXCL2. Additionally, the silencing of CXCR2 in GIST cells inhibited the metastasis promoting effect of CXCL2. Animal studies further confirmed that CXCL2 promoted liver metastasis of GIST in vivo. This study preliminarily revealed the mechanism of M2-TAM promoting tumor metastasis by secreting CXCL2 in GIST tumor microenvironment, and proffered theoretical reference for the development of immunotherapy strategies targeting M2-TAM.

Effect of tumor location on the efficacy of chemotherapy for gastrointestinal stromal tumors.

790 Background: Gastrointestinal stromal tumors (GISTs) arise from multiple sites within the gastrointestinal tract. Since the introduction of imatinib in 2002, patients have seen improved overall survival. However, a recent National Cancer Database (NCDB) study suggested no survival benefit to adjuvant imatinib for colorectal GIST patients. Another recent study showed that small bowel GISTs have larger median tumor size and higher incidence of tumors with at least 5 mitoses compared to gastric GISTs. These findings suggest a differential tumor biology for GISTs arising from different primary tumor sites, potentially conferring differential response to imatinib. In this NCDB study, we compare overall survival outcomes with and without chemotherapy, stratifying by primary tumor site. Methods: We queried the NCDB from 2004-2018 for patients with GIST histology. We excluded patients with age &lt;40, age&gt;80, high comorbidity score, and patients who received additional therapy other than surgery or chemotherapy. Of the 22,846 patients meeting criteria for our study, 27 patients had tumors originating from the anus, 454 from the colon, 173 from the esophagus, 15,296 from the stomach, 556 from the rectum, 32 from the rectosigmoid junction, and 6,308 from the small intestine. 8,983 (39%) received chemotherapy. Treatment with chemotherapy was used to extrapolate response to imatinib, the mainstay of treatment. Results: Cox proportional hazards analysis demonstrated increased hazard of death for chemotherapy, increasing age, and comorbidity score of 1. Positive predictive factors for survival included female sex and later year of diagnosis. For anal, esophageal, gastric, and rectosigmoid GIST patients, there was no statistically significant overall survival benefit for any treatment modality. For colonic GISTs, neoadjuvant chemotherapy combined with surgery improved overall survival. For rectal GISTs, adjuvant chemotherapy with surgery also provided survival benefit. For small intestinal GISTs, surgery alone or surgery with neoadjuvant, adjuvant, or both neoadjuvant and adjuvant chemotherapy improved overall survival. Conclusions: While our study is retrospective and limited as a NCDB study, our Kaplan-Meier survival analysis demonstrated survival benefit for chemotherapy only in patients with colon, rectal, or small intestinal GIST tumors. Our Cox proportional analysis demonstrated an overall negative survival impact for chemotherapy. These findings lend further support to the idea that differential tumor biology at each primary site may lead to differential response to imatinib. Overall, our study provides rationale for further investigating the heterogeneity of GIST tumor microenvironments, as these differences could contribute to the differential treatment outcomes.

Reporte de caso: Tumor del estroma gastrointestinal (GIST) en yeyuno

Gastrointestinalstromaltumors(GIST)aremesenchymalneoplasmsthatrepresentlessthan3%of gastrointestinal neoplasms, with an incidence of 1 to 2 cases per hundred thousand inhabitants. It originates more frequently in the stomach and small intestine and is characterized by the expression of the tyrosine kinase growth factor receptor, CD117. Therefore, its diagnosis requires an immunohischemical study to rule it out from other mesenchymal tumors. However, enteroscopic imaging and analysis of the biopsy may suggest a preoperative diagnosis of probable GIST. The case of a 62-year-old woman with rectorrhagia and recurrent anemia caused by mid-intestinal bleeding observed by capsule endoscopy is reported. Enteroscopy revealed a subepithelial ulcerated lesion in the proximal jejunum, and a biopsy was taken, the anatomopathological study of which suggested a gastrointestinal stromal tumor. The biopsy sample subjected to immunohistochemical studies conrms the suspicion of a cKit/CD117-positive GIST tumor. Surgical resection of the tumor with dimensions 4.2x3 cm is performed. After surgery, the patient was stable and under clinical follow-up until she was discharged. Clinical ndings, diagnosis and timely treatment contribute to increasing survival from complications.

The microphthalmia-associated transcription factor is involved in gastrointestinal stromal tumor growth.

Gastrointestinal stromal tumors (GISTs) are the most common neoplasms of mesenchymal origin, and most of them emerge due to the oncogenic activation of KIT or PDGFRA receptors. Despite their relevance in GIST oncogenesis, critical intermediates mediating the KIT/PDGFRA transforming program remain mostly unknown. Previously, we found that the adaptor molecule SH3BP2 was involved in GIST cell survival, likely due to the co-regulation of the expression of KIT and Microphthalmia-associated transcription factor (MITF). Remarkably, MITF reconstitution restored KIT expression levels in SH3BP2 silenced cells and restored cell viability. This study aimed to analyze MITF as a novel driver of KIT transforming program in GIST. Firstly, MITF isoforms were characterized in GIST cell lines and GIST patients' samples. MITF silencing decreases cell viability and increases apoptosis in GIST cell lines irrespective of the type of KIT primary or secondary mutation. Additionally, MITF silencing leads to cell cycle arrest and impaired tumor growth in vivo. Interestingly, MITF silencing also affects ETV1 expression, a linage survival factor in GIST that promotes tumorigenesis and is directly regulated by KIT signaling. Altogether, these results point to MITF as a key target of KIT/PDGFRA oncogenic signaling for GIST survival and tumor growth.

S2624 Massive Bleeding From Small Bowel GIST Tumor in Young Woman With Neurofibromatosis

Introduction: Gastrointestinal (GI) bleeding can be severe on presentation with associated hypotension and acute anemia. Common causes of upper GI bleeding in young patients include varices, Mallory Weiss tears, peptic ulcer disease, and angiodysplasia. Tumors within the GI tract are a less likely etiology. Here we present a rare case of a young woman with a massive GI bleed from a small bowel Gastrointestinal Stromal Tumor (GIST). Case Description/Methods: The patient is a 24-year-old female who presented to our emergency department with hematemesis, hematochezia, hypotension, increased BUN, acute drop of Hg, and an elevated lactate. After resuscitation with IVF and blood transfusion, she underwent an urgent endoscopy with gastritis, but no active bleeding. While being considered for a colonoscopy, she further decompensated with hemodynamic instability and recurrent hematochezia requiring transfer to the ICU. Urgent CT angiography was performed in an attempt to localize a bleeding source, which revealing an area in the proximal jejunum with extensive hypervascularity in the arterial phase, but no active bleeding (A). Subsequent push enteroscopy showed a large submucosal lesion in mid jejunum with focal ulceration (B, C). She promptly underwent surgical resection and pathology revealed a GIST. On further discussion with the patient’s family, it was later discovered that in the patient’s childhood, she had undergone evaluation for faint and scattered skin lesions suggestive of café au late spots, with work up consistent with Neurofibromatosis 1 (NF1) (Figure 1). Discussion: GISTs are overall uncommon tumors, accounting for only 0.1-3% of all neoplasms in the GI tract. In the general population, GIST tumors are most often discovered in the stomach. However, patients with NF1 have an increased risk for developing multifocal small bowel GISTs. While GI bleeding may be the initial presentation for such lesions, massive bleeding, as seen in this case, is an uncommon presentation. This case reinforces the importance of obtaining a thorough and detailed history to help create a proper differential in our patients.Figure 1.: A, CT angiogram showing hyper-vascular area in jejunum. B, Push enteroscopy showing ulcerated mass in jejunum. C, Push enteroscopy showing mass in jejunum.

Methyltransferase-like 3 (METTL3) mediated N6-methyladenosine (m6A) modifications facilitate mir-25-3p maturation to promote gastrointestinal stromal tumors (GISTs) progression.

Methyltransferase-like 3 (METTL3) is an RNA N6-methyladenosine (m6A) methyltransferase, which plays a critical role in micorRNA (miRNAs) processing and maturation, but it is still unclear whether METTL3 regulated miRNAs participates in the regulation of cancer aggressiveness in gastrointestinal stromal tumors (GISTs). This study was designed to investigate this issue, and uncover the potential underlying mechanisms. the expression of METTL3 in GISTs tissues and cell lines were determined by RT-qPCR and Western blot. Cell proliferation and migration were assessed by colony formation, CCK-8 and Transwell. The mRNA expression of all proteins was detected by RT-qPCR, and tumor xenograft study was applied to confirm the effect of METTL3 on GISTs development in vivo. In our study, we showed that METTL3 was significantly upregulated in GISTs tissues and cell lines. Functional experiments demonstrated that overexpression of METTL3 promoted GISTs cell malignant biological behavior and tumor growth in vitro and in vivo, and conversely, silencing of METTL3 had opposite effects and suppressed GISTs progression. Further mechanistical experiments verified that METTL3 promoted the maturation of miR-25-3p in an m6A-dependent manner. Similar to METTL3, miR-25-3p was also validated as an oncogene to promote cancer development in GISTs. Finally, our rescuing experiments hinted that silencing of miR-25-3p abrogated the tumor-initiating effects of METTL3 overexpression on GISTs. Collectively, those results indicated that METTL3 played an oncogenic role in GISTs through positively modulating the miR-25-3p in an m6A-dependent manner, and we firstly discussed how the METTL3/m6A/miR-25-3p axis affected GISTs development.

Clinical outcomes of endoscopic treatment for gastric gastrointestinal stromal tumors: a single-center study of 240 cases in China

Background and aims Endoscopic resection (ER) gradually becomes an important treatment method for gastrointestinal stromal tumors (GISTs). The aim of this study is to evaluate the efficacy and safety of ER of gastric GISTs. Methods This retrospective study included 240 patients with gastric GISTs who underwent ER at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology from January 2010 to December 2019. The clinicopathologic, endoscopic and follow-up data of the patients were collected and analyzed. Results The mean maximum tumor diameter was 1.67 ± 1.00 cm (range 0.2–6.5 cm), of which 156 cases (65.00%) were small gastric GISTs (tumor diameter < 2 cm). A total of 43 patients (17.92%) had perioperative bleeding, including 40 cases (16.67%) of minor bleeding and three cases (1.25%) of major bleeding. Perioperative perforation occurred in 101 patients (42.08%), of which 51 patients (21.25%) were active perforation and 50 patients (20.83%) were passive perforation. The en bloc resection rate was 97.08% (233/240), and seven cases (2.92%) had piecemeal resection. There were three cases (1.92%) of small gastric GISTs at intermediate risk and one case (0.64%) at high risk. A total of 193 patients were followed up, and no tumor residual, recurrence or metastasis occurred within a median follow-up time of 30 months (range 1–127 months). Conclusions Endoscopic treatment for gastric GISTs is safe and effective. Piecemeal resection does not seem to be related to the patient's prognosis. Endoscopic resection can be performed if patients are willing to remove small gastric GISTs.

Clinicopathological Study of Duodenal Gastrointestinal Stromal Tumors (GIST)

Objectives: Tumors of the gastrointestinal tract (GIST) are the most commonly seen tumors of the gut. The current study aimed to evaluate the clinical and pathological features of gastrointestinal stromal tumors presented in our setting. Methodology: A prospective observational study was conducted at a tertiary care center, Pakistan between January 2019 to March 2021. All cases of duodenal and stomach gastrointestinal stromal tumors diagnosed and treated at our center were analyzed in our study. All clinicopathological tumors including patient characteristics, treatments, histological examinations, and Genomic mutation were documented. The clinicopathologic parameters were compared between stomach and duodenal GIST. Results: A total of 221 patients were enrolled in the study. The majority were below the age of sixty years. The male to female ratio was 0.97. The most common presenting symptom was active bleeding or severe anemia with a frequency of 114 (51.6%). The majority of the duodenal GIST were present in the descending portion. 147 (66.5%) patients were offered limited resection while 25.8% were offered pancreaticoduodenectomy, and the remainder were not operated. About 30 (13.6%) patients had genetic mutation. Of these, the majority had a KIT mutation. In four patients, KIT and PDGFRA were both mutated. We stratified the patients with respect to the clinicopathological factors and found that tumor size was significantly associated with duodenal GIST (p&lt;0.001). Tumor size of &gt; 10 cm was more frequently found in duodenum than stomach &gt;10 [26 (11.8%) vs. 21 (6.7%)]. Conclusion: The present study highlights the clinicopathological pattern of GIST in our population. Furthermore, it indicated that the tumor size was significantly greater in patients diagnosed with duodenal GIST as compared to stomach GIST. Keywords: Duodenum, GIST, gastrointestinal stromal tumors, stomach adenocarcinoma

Gastric and small intestine gastrointestinal stromal tumors: our experience

Background: Gastrointestinal stromal tumors (GIST) are rare, although their incidence has increased in recent years. They are characterized by presenting a mutation in the c-Kit gene (CD117). The most common location is the stomach, followed by the small intestine and less frequently in the large intestine, esophagus, and mesentery. The main prognostic factors are the mitotic index and tumor size, and the main treatment is surgical resection. The spread is mainly hepatic and peritoneal. The objective of this study is to present our departments’ experience in the surgical treatment and long-term outcomes of GIST tumors in the stomach and small intestine.

Differential Diagnosis and Molecular Stratification of Gastrointestinal Stromal Tumors on CT Images Using a Radiomics Approach

Treatment planning of gastrointestinal stromal tumors (GISTs) includes distinguishing GISTs from other intra-abdominal tumors and GISTs’ molecular analysis. The aim of this study was to evaluate radiomics for distinguishing GISTs from other intra-abdominal tumors, and in GISTs, predict the c-KIT, PDGFRA, BRAF mutational status, and mitotic index (MI). Patients diagnosed at the Erasmus MC between 2004 and 2017, with GIST or non-GIST intra-abdominal tumors and a contrast-enhanced venous-phase CT, were retrospectively included. Tumors were segmented, from which 564 image features were extracted. Prediction models were constructed using a combination of machine learning approaches. The evaluation was performed in a 100 × random-split cross-validation. Model performance was compared to that of three radiologists. One hundred twenty-five GISTs and 122 non-GISTs were included. The GIST vs. non-GIST radiomics model had a mean area under the curve (AUC) of 0.77. Three radiologists had an AUC of 0.69, 0.76, and 0.84, respectively. The radiomics model had an AUC of 0.52 for c-KIT, 0.56 for c-KIT exon 11, and 0.52 for the MI. The numbers of PDGFRA, BRAF, and other c-KIT mutations were too low for analysis. Our radiomics model was able to distinguish GISTs from non-GISTs with a performance similar to three radiologists, but less observer dependent. Therefore, it may aid in the early diagnosis of GIST, facilitating rapid referral to specialized treatment centers. As the model was not able to predict any genetic or molecular features, it cannot aid in treatment planning yet.

Characteristics and clinical significance of lipid metabolism in patients with gastrointestinal stromal tumor

BackgroundTo investigate the characteristics and clinical significance of serum lipids in patients with gastrointestinal stromal tumors (GISTs).MethodsThe clinical and pathological data of 694 GIST patients in Liyuan hospital and Union hospital from 2012 to 2016 were retrospectively analyzed. Blood lipid levels in patients with varying degrees of risk were compared.ResultsThe findings showed that LDL-C, HDL-C, and CHOL increased significantly in women, and CD34 positive. In patients with tumors size less than 5 cm in diameter, TG, HDL-C, and CHOL were significantly higher. TG levels were significantly higher in DOG-1 (a marker and has a high specificity and sensitivity in the diagnosis of GIST) positive patients than in DOG-1 negative patients (P < 0.05). S-100 positive patients had lower HDL-C levels than S-100 negative patients (P < 0.05). Lipids indexes were found to be correlated with GIST risk stratification and tumor site (P < 0.05). TG/HDL-C was were significantly different among patients with GIST in different locations (P < 0.05).ConclusionThe clinical and pathological characteristics of the patients with GIST are closely related to the level of blood lipids. To a certain extent, information about level of blood lipids can be helpful for distinguishing benign and malignant GIST.

Clinico Pathologic Features and Prognostic Grouping of Gastrointestinal Stromal Tumors (GISTS) in Peshawar: an Institutional Perspective

Background: Gastrointestinal stromal tumours (GISTS) are uncommon gastrointestinal tumours. The prognosis is heavily influenced by the histopathologic features of resection specimens, which have not been investigated extensively in our community. Objective of the current study was to assess the histopathologic features of GISTs in our community, as well as how they affect their prognosis, based on what we found. Methodology: In this study, 60 cases of GISTs were included that were found and treated at Peshawar's Khyber Teaching Hospital from Jan, 2018 to December, 2020. Results: The patients' ages varied from 18 to 71 years. The stomach was the most common location for primary GISTs, accounting for 57.7% of cases.75% of the patients had spindle cell morphology, and 53.8 percent of them had a poor prognosis. It was shown that intestinal GISTs had a higher grade (70%) and were more likely to be in the elevated-risk prognosis groups than stomach gastrointestinal stromal tumor,(43 percent). However, there is no statistical difference found. Although GISTs are rare gastro-intestinal tumors, initial discovery and recognition of unfavorable histology properties are important for effective treatment. In stomach the GISTs is prevalent. However, intestinal gastrointestinal stromal tumors are shown to be more prevalent and more likely to be linked to poor prognostic factors. Moreover, further large-scale investigations are needed to confirm this conclusion. Keywords: Intestinal-GISTs, Stomach-GISTs, Peshawar, Gastrointestinal stromal tumors,

Identification of New Tumor-Related Gene Mutations in Chinese Gastrointestinal Stromal Tumors.

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. As the main GIST drivers, gain-of-function mutations in KIT or PDGFRA are closely associated with not only tumor development and progression but also therapeutic response. In addition to the status of KIT and PDGFRA, little is known about other potential GIST-related genes. In this study, we identified the mutation profiles in 49 KIT-mutated GIST tumors using the whole exome sequencing (WES) method. Furthermore, some representative mutations were further validated in an independent GIST cohort using the SNaPshot SNP assay. We identified extensive and diverse mutations of KIT in GIST, including many undescribed variants. In addition, we revealed some new tumor-related gene mutations with unknown pathogenicity. By enrichment analyses of gene function and protein-protein interaction network construction, we showed that these genes were enriched in several important cancer- or metabolism-related signaling pathways, including PI3K-AKT,RTK-RAS, Notch, Wnt, Hippo, mTOR, AMPK, and insulin signaling. In particular, DNA repair-related genes, including MLH1, MSH6, BRCA1, BRCA2, and POLE, are frequently mutated in GISTs, suggesting that immune checkpoint blockade may have promising clinical applications for these GIST subpopulations. In conclusion, in addition to extensive and diverse mutations of KIT, some genes related to DNA-repair and cell metabolism may play important roles in the development, progression and therapeutic response of GIST.